Pharmalaw was established to provide the pharmaceutical and chemical industry with a legal partner who understands science and the impact of intellectual property rights and the regulatory environment on the commercialisation of research products.
A multidisciplinary insight is provided which bridges the gap between science and the law and enables a legal and scientific service reaching from molecule to final drug product. Furthermore, many years of retail pharmacy experience also allows the provision of legal advice to this sector.
Pharmalaw functions as part of a cluster of expert consultants.
We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new drugs are central to any control strategy and the fastest route to tuberculosis elimination.
The consortium brings together a group of scientists from more that 14 countries with skills in clinical trials, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service.